Figure 1.
![Figure 1. Percentage of patients with severe cGVHD in 3 randomized trials. (GITMO,6,7 Finke,8,9 Kröger,10 and combined data [total] are shown).](https://ash.silverchair-cdn.com/ash/content_public/journal/bloodadvances/1/9/10.1182_bloodadvances.2016001560/3/advances001560f1.jpeg?Expires=1735841460&Signature=0q-qCaE00xEnAXBKViHp1jv796tfIamVmFxGkPdu2GJKUgq~IUQwHuaH6KergENNS~Rg5gIsq32TJT4d2z0cW-y9b9hewOF5xrbWO6JxVNIlORs0DSOpjd~GqfLisYOsER8IW27~owr14PAEfWZLUut8bcqGYMGwBikIiORxBX9VXgfKJJQWNGFIg8tBO-AGJJhd7Bpz-De1NwHNfySyxwxcDBNqpxc2jyXb80Th3QgTyvxSiNoZjWKClTOfelMXgp8eO9tqhJwELFFQaDkLRey98XLFTdqegsI~OvNKPCKiMY23bnQ2lG9n77yZrB6Ukg4G-LhnMm8CMbkkn6wZFQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Percentage of patients with severe cGVHD in 3 randomized trials. (GITMO,6,7 Finke,8,9 Kröger,10 and combined data [total] are shown).
Percentage of patients with severe cGVHD in 3 randomized trials. (GITMO,6,7 Finke,8,9 Kröger,10 and combined data [total] are shown).
